HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
NHLBI will fund a Clinical Trial Center and up to seven Clinical Centers to coordinate and conduct precision clinical trials for heart failure, focusing on patient recruitment, deep phenotyping, and personalized treatments.
Funder: National Institutes of Health
Due Dates: July 9, 2026
Funding Amounts: Up to $500,000 per award; total program funding estimated at $3,465,000; up to 8 awards; typically 1 year duration.
Summary: Supports a Clinical Trial Center and up to 7 Clinical Centers for precision clinical trials targeting heart failure with preserved ejection fraction (HFpEF).
Key Information: Applicants must specify either CTC or CC in their project title and use different PIs for each application.
Description
This opportunity, offered by the National Institutes of Health (NIH), solicits applications to establish a Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) as part of the HeartShare 2.0 program. The focus is on refining subtypes and treatment targets for heart failure with preserved ejection fraction (HFpEF) through precision clinical trials. The CTC will coordinate trial activities, develop master protocols, manage projects, oversee recruitment, monitor milestones, and ensure scientific rigor. CCs will recruit and retain HFpEF patients and controls, conduct deep phenotyping, obtain tissue biopsies, and support longitudinal follow-up and recruitment for future trials. Applicants can apply for either the CTC or a CC, but must use different Principal Investigators (PIs) for each application.
